Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E. Trillsch F, et al. Among authors: sehouli j. Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236. Epub 2016 Jun 10. Ann Oncol. 2016. PMID: 27287207 Free article. Clinical Trial.
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Onkologie. 2004 Feb;27(1):58-64. doi: 10.1159/000075607. Onkologie. 2004. PMID: 15007250 Clinical Trial.
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: sehouli j. Oncogene. 2005 Feb 3;24(6):1053-65. doi: 10.1038/sj.onc.1208298. Oncogene. 2005. PMID: 15558012
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
Sehouli J, Oskay-Ozcelik G, Kühne J, Stengel D, Hindenburg HJ, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Ann Oncol. 2006 Jun;17(6):957-61. doi: 10.1093/annonc/mdl079. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600975 Free article. Clinical Trial.
ErbB-3 predicts survival in ovarian cancer.
Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG. Tanner B, et al. Among authors: sehouli j. J Clin Oncol. 2006 Sep 10;24(26):4317-23. doi: 10.1200/JCO.2005.04.8397. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896008
764 results